The role of plasma lipids and inflammatory factors in the pathophysiology, clinical course and prognosis of heart failure of ischemic and non-ischemic

• Grant number: 13/04792-9
• Support Opportunities: Regular Research Grants
• Start date: February 01, 2014
• End date: January 31, 2016
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Antonio Carlos Pereira-Barretto
• Grantee: Antonio Carlos Pereira-Barretto
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Ana Elisa Marabini Martinelli ; Priscila Carvalho Melero da Silva ; Raul Cavalcante Maranhao

Abstract

Increased life expectancy of the population is accompanied by an increased incidence of heart failure (HF), a complex and progressive syndrome and very short survival. Higher levels of HDL-cholesterol are related with increased survival of these patients. HDL has several protective actions, as anti-inflammatory, vasodilatory, anti-aggregatory and antioxidant actions, in reverse transport and cholesterol esterification. Lipid transfer from HDL to other lipoproteins is an important step in the metabolism of HDL, and it is facilitated by transfer proteins, CETP and PLTP. MicroRNAs (miRNAs) are involved in the cholesterol efflux, an important step of reverse transport. The evaluation of the functional aspects of HDL can consolidate this lipoprotein as an important factor in the survival of HF, paving the way for the establishment of new prognostic markers and new therapeutic targets in this syndrome. The aim of this study is to investigate in advanced chronic HF, metabolic and functional aspects of HDL, such as lipid transfer to HDL and miRNAs expression involved in reverse transport. Correlation between these parameters with inflammatory factors and prognosis of these patients will also be performed. Four hundred patients will be allocated into four studied-groups: two of them with HF of ischemic origin with different stages, one with non-ischemic origin, and the control group with coronary artery disease without HF. Lipid transfer, mass and activity of CETP and PLTP will be performed by in vitro assays. HDL fraction of the participants will also be characterized in terms of particle size, antioxidant activity, and lipid and protein composition. Inflammatory factors will be determined by multiplex assays. MiRNAs expression will be performed using real time PCR approach. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MARTINELLI, ANA ELISA M.; MARANHAO, RAUL C.; CARVALHO, PRISCILA O.; FREITAS, FATIMA R.; SILVA, BRUNA M. O.; CURIATI, MILENA N. C.; KALIL FILHO, ROBERTO; PEREIRA-BARRETTO, ANTONIO CARLOS. Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure. LIPIDS IN HEALTH AND DISEASE, v. 17, OCT 20 2018. (13/04792-9)